
Vor Biopharma Inc.
VOR
Since 2015
Headquarters:
Exchange:
Industry:
Number of Employees:
Current Fiscal Year:
Market Cap:
Price per Share:
Quarterly Dividend per Share:
Price History
Latest Prices
Date | Open | High | Low | Close |
---|---|---|---|---|
2025-08-01 | 2.01 | 2.11 | 1.98 | 2.1 |
2025-07-31 | 2.2 | 2.3789 | 2.06 | 2.07 |
2025-07-30 | 2.29 | 2.32 | 2.15 | 2.21 |
2025-07-29 | 2.46 | 2.65 | 2.3 | 2.35 |
2025-07-28 | 2.25 | 2.56 | 2.235 | 2.42 |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.